Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).

Bailey CP, Figueroa M, Mohiuddin S, Zaky W, Chandra J.

Bioengineering (Basel). 2018 Oct 18;5(4). pii: E88. doi: 10.3390/bioengineering5040088. Review.

2.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
3.

The genetic signatures of pediatric high-grade glioma: no longer a one-act play.

Diaz AK, Baker SJ.

Semin Radiat Oncol. 2014 Oct;24(4):240-7. doi: 10.1016/j.semradonc.2014.06.003. Review.

4.

Signaling pathways and mesenchymal transition in pediatric high-grade glioma.

Meel MH, Schaper SA, Kaspers GJL, Hulleman E.

Cell Mol Life Sci. 2018 Mar;75(5):871-887. doi: 10.1007/s00018-017-2714-7. Epub 2017 Nov 21. Review.

5.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

PMID:
29760046
6.

Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.

Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA.

Acta Neuropathol Commun. 2018 Nov 5;6(1):117. doi: 10.1186/s40478-018-0614-1.

7.

Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma.

Hashizume R.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):331-342. doi: 10.2176/nmc.ra.2017-0018. Epub 2017 Jun 7. Review.

8.

Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic.

Morales La Madrid A, Hashizume R, Kieran MW.

Front Oncol. 2015 Jul 1;5:148. doi: 10.3389/fonc.2015.00148. eCollection 2015. Review.

9.

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.

Misuraca KL, Cordero FJ, Becher OJ.

Front Oncol. 2015 Jul 24;5:172. doi: 10.3389/fonc.2015.00172. eCollection 2015. Review.

10.

Genomic Insights into Diffuse Intrinsic Pontine Glioma.

Lapin DH, Tsoli M, Ziegler DS.

Front Oncol. 2017 Mar 28;7:57. doi: 10.3389/fonc.2017.00057. eCollection 2017. Review.

11.

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma.

Buczkowicz P, Hawkins C.

Front Oncol. 2015 Jun 30;5:147. doi: 10.3389/fonc.2015.00147. eCollection 2015. Review.

12.

Diffuse intrinsic pontine glioma: poised for progress.

Warren KE.

Front Oncol. 2012 Dec 28;2:205. doi: 10.3389/fonc.2012.00205. eCollection 2012.

13.

In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E.

PLoS One. 2013 Apr 29;8(4):e61512. doi: 10.1371/journal.pone.0061512. Print 2013.

14.

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.

Cockle JV, Brüning-Richardson A, Scott KJ, Thompson J, Kottke T, Morrison E, Ismail A, Carcaboso AM, Rose A, Selby P, Conner J, Picton S, Short S, Vile R, Melcher A, Ilett E.

Mol Ther Oncolytics. 2017 May 2;5:75-86. doi: 10.1016/j.omto.2017.04.002. eCollection 2017 Jun 16.

15.

Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

Gwak HS, Park HJ.

Crit Rev Oncol Hematol. 2017 Dec;120:111-119. doi: 10.1016/j.critrevonc.2017.10.013. Epub 2017 Oct 31. Review.

PMID:
29198324
16.

Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.

Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle B, Grundy R.

Neuro Oncol. 2011 Feb;13(2):212-22. doi: 10.1093/neuonc/noq158. Epub 2010 Dec 7.

17.

Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

Cohen KJ, Jabado N, Grill J.

Neuro Oncol. 2017 Aug 1;19(8):1025-1034. doi: 10.1093/neuonc/nox021. Review.

18.

DIPG in Children - What Can We Learn from the Past?

Vanan MI, Eisenstat DD.

Front Oncol. 2015 Oct 21;5:237. doi: 10.3389/fonc.2015.00237. eCollection 2015. Review.

19.

Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.

Panditharatna E, Yaeger K, Kilburn LB, Packer RJ, Nazarian J.

Cancer Genet. 2015 Jul-Aug;208(7-8):367-73. doi: 10.1016/j.cancergen.2015.04.008. Epub 2015 May 1. Review.

PMID:
26206682
20.

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.

Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ.

Acta Neuropathol Commun. 2014 Jun 3;2:59. doi: 10.1186/2051-5960-2-59.

Supplemental Content

Support Center